Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6456 USD | 0.00% | +0.72% | -13.41% |
May. 07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Financials (USD)
Sales 2024 * | 210K | Sales 2025 * | 300K | Capitalization | 13.61M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -28M | EV / Sales 2024 * | 64.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 45.4 x |
P/E ratio 2024 * |
-0.75
x | P/E ratio 2025 * |
-0.78
x | Employees | 18 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.39% |
Latest transcript on Traws Pharma, Inc.
1 week | +0.72% | ||
Current month | -2.18% | ||
1 month | -9.52% | ||
3 months | -7.11% | ||
6 months | -0.52% | ||
Current year | -13.41% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 13-08-31 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 15-06-30 |
Jack Stover
BRD | Director/Board Member | 69 | 16-05-22 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 20-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 0.6456 | 0.00% | 31,930 |
24-05-10 | 0.6456 | -0.53% | 32,910 |
24-05-09 | 0.649 | -0.21% | 55,748 |
24-05-08 | 0.6504 | -1.99% | 35,637 |
24-05-07 | 0.6636 | +3.53% | 53,229 |
Delayed Quote Nasdaq, May 13, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.41% | 13.61M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+42.10% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- TRAW Stock